Maria Stella Graziani

Deputy Director
Martina Zaninotto

Associate Editors
Ferruccio Ceriotti
Davide Giavarina
Bruna Lo Sasso
Giampaolo Merlini
Martina Montagnana
Andrea Mosca
Paola Pezzati
Rossella Tomaiuolo
Matteo Vidali

International Advisory Board Khosrow Adeli Canada
Sergio Bernardini Italy
Marcello Ciaccio Italy
Eleftherios Diamandis Canada
Philippe Gillery France
Kjell Grankvist Sweden
Hans Jacobs The Netherlands
Eric Kilpatrick UK
Magdalena Krintus Poland
Giuseppe Lippi Italy
☩Howard Morris Australia
Mario Plebani Italy
Sverre Sandberg Norway
Ana-Maria Simundic Croatia
☩Jill Tate Australia
Tommaso Trenti Italy
Cas Weykamp The Netherlands
Maria Willrich USA
Paul Yip Canada

Biomedia srl
Via L. Temolo 4, 20126 Milano

Responsible Editor
Giuseppe Agosta

Editorial Secretary
Arianna Lucini Paioni
Biomedia srl
Via L. Temolo 4, 20126 Milano
Tel. 0245498282
email: biochimica.clinica@sibioc.it

Area soci
Non possiedi o non ricordi la password!
Clicca qui

BC: Articoli scritti da B. Bonetti

Raccomandazioni per la rilevazione e la gestione dei campioni non idonei nei laboratori clinici
Recommendations for the detection and management of unsuitable samples in clinical laboratories
<p>A large body of evidence supports that quality improvement efforts tailored to the analytical phase only, are less likely to generate further clinical and economical progresses. Actually, most diagnostic errors made within the laboratory diagnostics emerge in the extra-analytical domains of testing, especially within the preanalytical phase. It is now clear that the underlying causes are most frequently due to system errors or to the implementation of poorly standardized procedures for collection, handling, transportation, preparation and storage of biospecimens. Some of these problems could generate a number of issues related to the quality of clinical samples, ending up with the reception by the laboratory of unsuitable samples. The identification and the management of unsuitable samples represent thus unavoidable practices in clinical laboratories to guarantee the quality of test results throughout the total testing process. Due to the ongoing evolution of the in vitro diagnostic market and the availability of new evidence, this paper provides a revision of the national recommendations issued by the Italian Society of Clinical Biochemistry and Clinical Molecular Biology in 2007 for detection and practical management of unsuitable specimens in clinical laboratories.</p>
Biochimica Clinica ; 44(2) 180-193
Documenti SIBioC - SIBioC Documents
Un approccio proteomico per l’identificazione di autoantigeni nell’encefalopatia di Hashimoto
A proteomic approach to identify autoantigens in Hashimoto’s encephalopathy
A. Farinazzo  |  B. Gini  |  G. Moretto  |  B. Bonetti  | 
<p>Hashimoto&rsquo;s encephalopathy (HE)&nbsp;is a syndrome involving the central nervous system (CNS), characterized by an heterogeneous clinical presentation with&nbsp;neurological and/or neuropsychiatric symptoms associated with high titers of anti-thyroid antibodies. Although the&nbsp;pathogenesis of HE is still unclear, the response to steroid treatment suggests that autoimmune mechanisms may be&nbsp;involved. To date, the role of anti-thyroid IgG as well as the identification of the antigen(s) targeted by IgG remain&nbsp;unknown. We performed a proteomic study on 19 patients with HE and 15 controls based on bidimensional&nbsp;electrophoresis (2D) of human CNS proteins followed by immunoblotting with cerebrospinal fluid (CSF) of patients. The&nbsp;comparative analysis of 2D maps showed that CSF IgG from HE patients specifically recognized 3 spots in a range of&nbsp;pH from 5 to 7 and of MW from 31 to 37 kDa amongst a wide autoreactivity to neural antigens. After mass spectrometry&nbsp;analysis and immunoblotting with specific antibodies, these proteins were identified as dimethylargininase-I (DDAHI) and&nbsp;aldehyde reductase-I (AKRIAI). Almost 90% of HE patients targeted at least one of two isoforms of DDAHI, while few&nbsp;cases recognized AKRIAI. The present findings suggest DDAHI and AKRIAI as biomarkers of HE although further&nbsp;experimental evidence is needed to understand their pathogenetic and diagnostic role, if any. Our 2D proteomic&nbsp;approach appears to be a sensitive and reliable method to assess the autoimmune repertoire in HE, helping to identify&nbsp;potential autoantigens in CSF and sera of HE patients.</p>
Biochimica Clinica ; 38(3) 222-226
Contributi scientifici - Scientific Papers